227 related articles for article (PubMed ID: 28659921)
1. Patient's Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers.
Messaoudene M; Frazao A; Gavlovsky PJ; Toubert A; Dulphy N; Caignard A
Front Immunol; 2017; 8():683. PubMed ID: 28659921
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapies: Friends or Foes for Patient's NK Cell-Mediated Tumor Immune-Surveillance?
Damele L; Ottonello S; Mingari MC; Pietra G; Vitale C
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32218226
[TBL] [Abstract][Full Text] [Related]
3. Natural Killers Are Made Not Born: How to Exploit NK Cells in Lung Malignancies.
Carrega P; Ferlazzo G
Front Immunol; 2017; 8():277. PubMed ID: 28348567
[TBL] [Abstract][Full Text] [Related]
4. Role of Distinct Natural Killer Cell Subsets in Anticancer Response.
Stabile H; Fionda C; Gismondi A; Santoni A
Front Immunol; 2017; 8():293. PubMed ID: 28360915
[TBL] [Abstract][Full Text] [Related]
5. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.
Ferrari de Andrade L; Ngiow SF; Stannard K; Rusakiewicz S; Kalimutho M; Khanna KK; Tey SK; Takeda K; Zitvogel L; Martinet L; Smyth MJ
Cancer Res; 2014 Dec; 74(24):7298-308. PubMed ID: 25351955
[TBL] [Abstract][Full Text] [Related]
6. Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity.
Dahlberg CI; Sarhan D; Chrobok M; Duru AD; Alici E
Front Immunol; 2015; 6():605. PubMed ID: 26648934
[TBL] [Abstract][Full Text] [Related]
7. Natural Killer Group 2D Ligand Depletion Reconstitutes Natural Killer Cell Immunosurveillance of Head and Neck Squamous Cell Carcinoma.
Weil S; Memmer S; Lechner A; Huppert V; Giannattasio A; Becker T; Müller-Runte A; Lampe K; Beutner D; Quaas A; Schubert R; Herrmann E; Steinle A; Koehl U; Walter L; von Bergwelt-Baildon MS; Koch J
Front Immunol; 2017; 8():387. PubMed ID: 28443091
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential and challenges of natural killer cells in treatment of solid tumors.
Gras Navarro A; Björklund AT; Chekenya M
Front Immunol; 2015; 6():202. PubMed ID: 25972872
[TBL] [Abstract][Full Text] [Related]
9. Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance.
Zingoni A; Fionda C; Borrelli C; Cippitelli M; Santoni A; Soriani A
Front Immunol; 2017; 8():1194. PubMed ID: 28993779
[TBL] [Abstract][Full Text] [Related]
10. Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy.
Chester C; Fritsch K; Kohrt HE
Front Immunol; 2015; 6():601. PubMed ID: 26697006
[TBL] [Abstract][Full Text] [Related]
11. Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity.
Pasero C; Gravis G; Guerin M; Granjeaud S; Thomassin-Piana J; Rocchi P; Paciencia-Gros M; Poizat F; Bentobji M; Azario-Cheillan F; Walz J; Salem N; Brunelle S; Moretta A; Olive D
Cancer Res; 2016 Apr; 76(8):2153-65. PubMed ID: 27197252
[TBL] [Abstract][Full Text] [Related]
12. Shaping of Natural Killer Cell Antitumor Activity by
Granzin M; Wagner J; Köhl U; Cerwenka A; Huppert V; Ullrich E
Front Immunol; 2017; 8():458. PubMed ID: 28491060
[TBL] [Abstract][Full Text] [Related]
13. Natural Killer Cell-Based Cancer Immunotherapies: From Immune Evasion to Promising Targeted Cellular Therapies.
Hofer E; Koehl U
Front Immunol; 2017; 8():745. PubMed ID: 28747910
[TBL] [Abstract][Full Text] [Related]
14. A New Biological Feature of Natural Killer Cells: The Recognition of Solid Tumor-Derived Cancer Stem Cells.
Tallerico R; Garofalo C; Carbone E
Front Immunol; 2016; 7():179. PubMed ID: 27242786
[TBL] [Abstract][Full Text] [Related]
15. Natural killer cells and solid tumors.
Stojanovic A; Cerwenka A
J Innate Immun; 2011; 3(4):355-64. PubMed ID: 21502747
[TBL] [Abstract][Full Text] [Related]
16. Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells.
Dulphy N; Chrétien AS; Khaznadar Z; Fauriat C; Nanbakhsh A; Caignard A; Chouaib S; Olive D; Toubert A
Front Immunol; 2016; 7():94. PubMed ID: 27014273
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors.
Raja Gabaglia C; Diaz de Durana Y; Graham FL; Gauldie J; Sercarz EE; Braciak TA
Cancer Res; 2007 Mar; 67(5):2290-7. PubMed ID: 17332360
[TBL] [Abstract][Full Text] [Related]
18. The nexus of natural killer cells and melanoma tumor microenvironment: crosstalk, chemotherapeutic potential, and innovative NK cell-based therapeutic strategies.
Rahimi A; Malakoutikhah Z; Rahimmanesh I; Ferns GA; Nedaeinia R; Ishaghi SMM; Dana N; Haghjooy Javanmard S
Cancer Cell Int; 2023 Dec; 23(1):312. PubMed ID: 38057843
[TBL] [Abstract][Full Text] [Related]
19. A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma.
Wang T; Sun F; Xie W; Tang M; He H; Jia X; Tian X; Wang M; Zhang J
Cancer Lett; 2016 Mar; 372(2):166-78. PubMed ID: 26791237
[TBL] [Abstract][Full Text] [Related]
20. Immunological and Translational Aspects of NK Cell-Based Antitumor Immunotherapies.
Shevtsov M; Multhoff G
Front Immunol; 2016; 7():492. PubMed ID: 27891129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
